The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
High-Fat Diet–Induced Neuropathy of Pre-Diabetes and Obesity
Open accessAbstract
OBJECTIVE—Subjects with dietary obesity and pre-diabetes have an increased risk for developing both nerve conduction slowing and small sensory fiber neuropathy. Animal models of this type of neuropathy have not been described. This study evaluated neuropathic changes and their amenability to dietary and pharmacological interventions in mice fed a high-fat diet (HFD), a model of pre-diabetes and alimentary obesity. RESEARCH DESIGN AND METHODS—Female C57BL6/J mice were fed normal diets or HFDs for 16 weeks. RESULTS—HFD-fed mice developed obesity, increased plasma FFA and insulin concentrations, and impaired glucose tolerance. They also had motor and sensory nerve conduction deficits, tactile allodynia, and thermal hypoalgesia in the absence of intraepidermal nerve fiber loss or axonal atrophy. Despite the absence of overt hyperglycemia, the mice displayed augmented sorbitol pathway activity in the peripheral nerve, as well as 4-hydroxynonenal adduct nitrotyrosine and poly(ADP-ribose) accumulation and 12/15-lipoxygenase overexpression in peripheral nerve and dorsal root ganglion neurons. A 6-week feeding with normal chow after 16 weeks on HFD alleviated tactile allodynia and essentially corrected thermal hypoalgesia and sensory nerve conduction deficit without affecting motor nerve conduction slowing. Normal chow containing the aldose reductase inhibitor fidarestat (16 mg · kg−1· day −1) corrected all functional changes of HFD-induced neuropathy. CONCLUSIONS—Similar to human subjects with pre-diabetes and obesity, HFD-fed mice develop peripheral nerve functional, but not structural, abnormalities and, therefore, are a suitable model for evaluating dietary and pharmacological approaches to halt progression and reverse diabetic neuropathy at the earliest stage of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Towbin, H., Staehelin, T., & Gordon, J. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.9.4350 · Cited by 53,385
Quantitative assessment of tactile allodynia in the rat paw
Chaplan, S. R., Bach, F. W., Pogrel, J. W., Chung, J. M., & Yaksh, T. L. (1994) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(94)90144-9 · Cited by 7,697
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors
Jagtap, P., & Szabó, C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1718 · Cited by 896
Epidemiologic and economic consequences of the global epidemics of obesity and diabetes
Yach, D., Stuckler, D., & Brownell, K. D. (2006) · Nature Medicine · doi:10.1038/nm0106-62 · Cited by 867
The spectrum of neuropathy in diabetes and impaired glucose tolerance
Sumner, C. J., Sheth, S., Griffin, J. W., Cornblath, D. R., & Polydefkis, M. (2003) · Neurology · doi:10.1212/wnl.60.1.108 · Cited by 708
Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation
Garcia Soriano, F., Virág, L., Jagtap, P., Szabó, É., Mabley, J. G., Liaudet, L., Marton, A., Hoyt, D. G., Murthy, K. G. K., Salzman, A. L., et al. (2001) · Nature Medicine · doi:10.1038/83241 · Cited by 603
Lifestyle intervention for pre-diabetic neuropathy
Smith, A. G., Russell, J., Feldman, E. L., Goldstein, J., Peltier, A., Smith, S., Hamwi, J., Pollari, D., Bixby, B., Howard, J., et al. (2006) · Diabetes Care · doi:10.2337/dc06-0224 · Cited by 585
Towbin, H. (1992) · Biotechnology(Faisalabad) · Cited by 453
Becker, J., Nora, D. B., Gomes, I., Stringari, F. F., Seitensus, R., Panosso, J. S., & Ehlers, J. A. C. (2002) · Clinical Neurophysiology · doi:10.1016/s1388-2457(02)00201-8 · Cited by 395
Nagamatsu, M., Nickander, K. K., Schmelzer, J. D., Raya, A., Wittrock, D. A., Tritschler, H., & Low, P. A. (1995) · Diabetes Care · doi:10.2337/diacare.18.8.1160 · Cited by 378
Cited by
Mechanisms of Diabetic Complications
Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890
Giri, B., Dey, S., Das, T., Sarkar, M., Banerjee, J., & Dash, S. K. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.07.157 · Cited by 635
Diabetic neuropathy: cellular mechanisms as therapeutic targets
Vincent, A. M., Callaghan, B. C., Smith, A. L., & Feldman, E. L. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.137 · Cited by 566
Mechanism of diabetic neuropathy: Where are we now and where to go?
Yagihashi, S., Mizukami, H., & Sugimoto, K. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00070.x · Cited by 488
Myelin Fat Facts: An Overview of Lipids and Fatty Acid Metabolism
Poitelon, Y., Kopec, A. M., & Belin, S. (2020) · Cells · doi:10.3390/cells9040812 · Cited by 394
Emerging role of 12/15-Lipoxygenase (ALOX15) in human pathologies
Singh, N. K., & Rao, G. N. (2019) · Progress in Lipid Research · doi:10.1016/j.plipres.2018.11.001 · Cited by 345
Functional and pathological roles of the 12- and 15-lipoxygenases
Dobrian, A. D., Lieb, D. C., Cole, B. K., Taylor-Fishwick, D. A., Chakrabarti, S. K., & Nadler, J. L. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2010.10.005 · Cited by 324
Self-citationArnold, S. E., Lucki, I., Brookshire, B. R., Carlson, G. C., Browne, C. A., Kazi, H., Bang, S., Choi, B.-R., Chen, Y., McMullen, M. F., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.03.011 · Cited by 314
Schwann cell interactions with axons and microvessels in diabetic neuropathy
Gonçalves, N. P., Vægter, C. B., Andersen, H., Østergaard, L., Calcutt, N. A., & Jensen, T. S. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.201 · Cited by 305
Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets
Dewanjee, S., Das, S., Das, A. K., Bhattacharjee, N., Dihingia, A., Dua, T. K., Kalita, J., & Manna, P. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.06.034 · Cited by 300
Inflammation and neuropeptides: the connection in diabetic wound healing
Pradhan, L., Nabzdyk, C., Andersen, N. D., LoGerfo, F. W., & Veves, A. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409000945 · Cited by 285
Mechanisms of disease: The oxidative stress theory of diabetic neuropathy
Figueroa-Romero, C., Sadidi, M., & Feldman, E. L. (2008) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-008-9104-2 · Cited by 284
Diabetic Painful and Insensate Neuropathy: Pathogenesis and Potential Treatments
Obrosova, I. G. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.07.004 · Cited by 272
Self-citationObesity and hyperlipidemia are risk factors for early diabetic neuropathy
Smith, A. G., & Singleton, J. R. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.04.003 · Cited by 272
Dyslipidemia-Induced Neuropathy in Mice
Vincent, A. M., Hayes, J. M., McLean, L. L., Vivekanandan-Giri, A., Pennathur, S., & Feldman, E. L. (2009) · Diabetes · doi:10.2337/db09-0047 · Cited by 264
Yarandi, S. S., & Srinivasan, S. (2014) · Neurogastroenterology & Motility · doi:10.1111/nmo.12330 · Cited by 236
Fan, L., Cacicedo, J. M., & Ido, Y. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13303 · Cited by 86
Pai, Y.-W., Tang, C.-L., Lin, C.-H., Lin, S.-Y., Lee, I.-T., & Chang, M.-H. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.04.004 · Cited by 20
Lipids, lipid-lowering therapy, and neuropathy: a narrative review
Pasha, R., Azmi, S., Ferdousi, M., Kalteniece, A., Bashir, B., Gouni-Berthold, I., Malik, R. A., & Soran, H. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.03.013 · Cited by 18
Metadata
- Authors
- Obrosova, I. G., Ilnytska, O., Lyzogubov, V. V., Pavlov, I. A., Mashtalir, N., Nadler, J. L., & Drel, V. R.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2007-10-01
- Volume
- 56
- Issue
- 10
- Pages
- 2598-2608
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2122571652
- Cited by
- 262
- References
- 49
- FWCI
- 7.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.